Andorra vs Sierra Leone: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Andorra
93.0%
in 2025
Sierra Leone
93.0%
in 2025
Andorra rank
51st
Sierra Leone rank
51st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Andorra
- Sierra Leone
How they compare
Andorra currently reports 93.0% against 93.0% in Sierra Leone, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Sierra Leone ahead.
Andorra ranks 51st and Sierra Leone ranks 51st of 192 countries.
Across the 3 decades both report, Andorra averaged higher in 1 and Sierra Leone in 1.
Head to head by decade
| Decade | Andorra | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 56.5% | 78.8% | 22.3% | Sierra Leone |
| 2020s | 94.8% | 92.2% | 2.7% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Andorra or Sierra Leone?
- Andorra, at 93.0% against 93.0% in Sierra Leone as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Andorra and Sierra Leone?
- 0.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Sierra Leone?
- 18 years are reported by both, from 2008 to 2025.
- How do Andorra and Sierra Leone rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Andorra ranks 51st and Sierra Leone ranks 51st of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.